US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor.
The company said the trials, which tested the drug as an option for moderate to severe hidradenitis suppurativa (HS), met their primary endpoints and showed a consistent safety profile.
The STOP-HS1 and STOP-HS2 studies assessed the proportion of patients achieving at least a 50% reduction in abscess and inflammatory nodule count without worsening of other symptoms. At 12 weeks, the response rates were around 40% for both the low and high doses, compared with approximately 30% in the placebo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze